Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Why shouldn't we do screening for lung cancer on everyone?
Author
Howard (Jack) West, MD

A post on About.com makes the case that screening the higher risk population of just those people 55-75 with a significant smoking history, as was done in the influential National Lung Cancer Screening Trial (NLST) published last year in the New England Journal of Medicine, would miss nearly 3 of 4 lung cancers even as this effort improves lung cancer survival by 20% in the screened population. This piece implies that broader screening across of a wider range of ages and smoking history would be appropriate in order to detect more lung cancer and improve outcomes.   So let me make two points.

1) I am a proponent of lung cancer screening for an appropriate population and think it's underutilized now.

2) It is categorically incorrect to presume that broadening screening to a wider population will lead to better outcomes.

Why?

The NLST paper was among the most important developments in lung cancer in recent years, and it does document a 20% improvement in overall survival in the screened population, who had a significant risk for lung cancer as defined by being old enough to have a greater probability of developing cancer, young enough to not have a high probability of competing risks limiting the ability to be treated for lung cancer, and enough of a smoking history that nodules found by screening would have a real probability of representing cancer vs. a benign finding like inflammation, infection, prior scarring, etc.  We also know that screening for lung cancer with chest CT scans detects many nodules that are not cancer, and this is associated with additional scans, a significant risk of pursuing invasive tests to chase down findings, and significant anxiety in those affected.  There is also some potential risk from the radiation administered with scanning, which we want to be minimal, and which is undefined over the long term.

Screening for any cancer makes sense if you can focus on the people with a high enough risk that the benefit exceeds the risks.  But there are risks, and not just the cost of doing CT scans tens of thousands of additional people every year (though that isn't trivial).  The more broadly screening is applied to a group at low risk for actually having cancer, or not being fit enough to pursue treatment for a cancer detected early (such as a 79 year-old with significant heart disease), the more likely screening will deliver the negative consequences without the benefits.  The yield of screening will decline dramatically if it is applied to younger patients and never-smokers or those with a minimal smoking history, and there is a far greater probability that any suspicious findings will entail the repeat scans, interventions, and anxiety without sufficient probability of a real cancer to counterbalance those factors. 

It is absolutely true that more lung cancers could be detected if screening is pursued for a very broad population, but the survival benefit would be diluted and potentially even lost in the face of a small but real risk from complications from invasive procedures or radiation over years and years of scans that aren't demonstrated to improve survival in a younger or older population, or those with a minimal or no smoking history.

I see lung cancer screening as being woefully underutilized today despite the evidence to support it, and I believe this is because most primary care physicians and very possibly most insurers remain unconvinced that the benefit is really "worth it" for the cost of the intervention.  That's a shame, but diluting the benefit by screening a much lower risk population is not the way to improve the situation.  The evidence supports screening a population with a high enough risk of lung cancer...but screening more isn't necessarily better.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on